Base Excision Repair: The DNA Glycosylase Flip-Out Mechanism

What BER Is and Where It Happens

Base excision repair is the primary defense against the constant chemical erosion of DNA bases. Unlike nucleotide excision repair, which handles bulky lesions that kink the helix, BER targets small lesions that barely distort the double helix—a deaminated cytosine (now uracil), an oxidized guanine (8-oxoG), an alkylated adenine (3-methyladenine), or an abasic (AP) site where a base has simply fallen off.

The pathway operates in both the nucleus and the mitochondria, and it is essentially universal—present in bacteria, archaea, and all eukaryotes. In humans it is the workhorse repair system, correcting on the order of 10,000-30,000 lesions per cell per day. Its importance is underscored by lethality data: knockout of the core enzymes APE1 (APEX1) or DNA polymerase β (POLB) is embryonic-lethal in mice, whereas many glycosylases are individually dispensable because their substrate ranges overlap. BER is also the terminal step of active DNA demethylation, linking it directly to epigenetic reprogramming.

The Mechanism, Step by Step

BER proceeds through a tightly coordinated hand-off in which each enzyme's product is the next enzyme's substrate—so the cytotoxic intermediates (AP sites, nicks) are never left exposed:

• 1. Recognition and base flipping. A lesion-specific DNA glycosylase slides along the duplex, bends the DNA ~45-70° at the target, and rotates the damaged base 180° out of the stack into its active-site pocket. A residue is inserted into the resulting gap to plug the helix.
• 2. Glycosidic bond cleavage. The glycosylase hydrolyzes the N-glycosidic bond, releasing the free base and leaving an apurinic/apyrimidinic (AP) site.
• 3. Backbone incision. APE1 nicks the phosphodiester backbone 5' to the AP site, generating a 3'-OH and a 5'-deoxyribose phosphate (5'-dRP).
• 4. Gap filling. DNA polymerase β removes the 5'-dRP with its lyase domain and inserts the correct nucleotide.
• 5. Ligation. The XRCC1–DNA ligase III complex seals the nick, restoring an intact strand.

Key Molecules and Characteristic Numbers

The specificity of BER comes from a family of ~11 human DNA glycosylases, each tuned to particular damage:

• UNG (uracil-DNA glycosylase) — removes uracil from C→U deamination or dUMP misincorporation; it is the enzyme Tomas Lindahl discovered in 1974 and is astonishingly efficient, flipping and cleaving uracil in milliseconds.
• OGG1 — excises 8-oxoguanine paired with cytosine; a bifunctional glycosylase with associated AP-lyase (β-elimination) activity.
• MUTYH — removes adenine mis-incorporated opposite 8-oxoG, preventing G:C→T:A transversions.
• MPG/AAG — excises alkylated purines like 3-methyladenine.

Glycosylases are classed as monofunctional (e.g., UNG—glycosylase only, needs APE1 to incise) or bifunctional (e.g., OGG1, NTH1—glycosylase plus AP-lyase). Short-patch BER replaces a single nucleotide; long-patch BER (using pol δ/ε, PCNA, and FEN1 to remove a flap) replaces 2-13 nucleotides when the 5' end is refractory to pol β's lyase.

How BER Is Studied and Regulated

Much of what we know comes from X-ray crystallography of glycosylase–DNA complexes, which captured the flipped-out base in the enzyme pocket—work pioneered on uracil-DNA glycosylase and HhaI methyltransferase in the mid-1990s by John Tainer, Gregory Verdine, Richard Roberts, and colleagues. Researchers use substrate DNA bearing a non-hydrolyzable base analog (e.g., pyrrolidine, or 2'-fluoro sugars) to trap the flipped intermediate, and single-molecule FRET to watch the base rotate in real time.

Functionally, activity is measured by oligonucleotide cleavage assays: a fluorescently labeled substrate is incubated with cell extract or purified enzyme, and product is resolved on a denaturing gel. Regulation is layered: XRCC1 acts as a scaffold that physically coordinates pol β, ligase III, and PARP1 to the lesion; PARP1 binds the strand break and recruits repair factors via PAR chains; and post-translational modifications (acetylation of APE1, ubiquitination of pol β) tune enzyme levels and localization. Cell-cycle phase and chromatin state also gate access—OGG1 must contend with nucleosome-wrapped DNA.

How BER Differs from Its Close Cousins

BER is easy to confuse with other excision pathways, but its logic is distinct:

• vs. Nucleotide excision repair (NER): NER recognizes the distortion a bulky lesion causes and excises a ~24-32 nt oligonucleotide; BER recognizes the specific chemical identity of one small base via a dedicated glycosylase and typically replaces just 1 nt.
• vs. Mismatch repair (MMR): MMR corrects normal but mispaired bases (replication errors) using strand-discrimination signals; BER removes bases that are chemically abnormal, and does not need to know which strand is 'correct.'
• vs. Direct reversal: Enzymes like MGMT (O6-methylguanine methyltransferase) and the AlkB dioxygenases undo damage in a single chemical step with no excision at all.

Critically, BER is the only pathway that begins with N-glycosidic bond hydrolysis, and the base-flipping recognition step is its signature—a mechanism it shares with, and likely borrowed evolutionarily from, DNA methyltransferases.

Significance, Disease, and Open Questions

Because BER guards against mutations that drive cancer and aging, its failure is medically consequential:

• MUTYH-associated polyposis (MAP): biallelic MUTYH mutations cause a colorectal cancer predisposition marked by characteristic G:C→T:A transversions, the mutational fingerprint of unrepaired 8-oxoG.
• Neurodegeneration: mitochondrial DNA relies heavily on BER, and deficits are implicated in Parkinson's and Alzheimer's, where oxidative 8-oxoG accumulates.
• Cancer therapy: BER is a drug target—PARP inhibitors (olaparib) and the AGT/pol β axis are exploited to sensitize tumors, and inhibiting BER can potentiate alkylating chemotherapies like temozolomide.

Open questions remain: How are the many glycosylases prioritized so that toxic AP-site intermediates are never orphaned? How does BER navigate nucleosomes and higher-order chromatin efficiently? And how is the same machinery repurposed for active DNA demethylation (via TET-generated 5-formyl/5-carboxylcytosine excised by TDG)—turning a repair pathway into an epigenetic eraser?

Base excision repair versus related DNA repair pathways

Feature	Base Excision Repair (BER)	Nucleotide Excision Repair (NER)	Mismatch Repair (MMR)
Lesion type	Small, non-bulky (uracil, 8-oxoG, alkyl, AP sites)	Bulky, helix-distorting (UV dimers, adducts)	Base-base mismatches, insertion/deletion loops
Recognition	Lesion-specific DNA glycosylase flips base out	Distortion sensed by XPC / CSB complexes	MutSα (MSH2-MSH6) scans for mispairs
Patch size	1 nt (short-patch) or 2-13 nt (long-patch)	~24-32 nt oligonucleotide excised	Up to ~1 kb re-synthesized
Key nuclease	APE1 (AP endonuclease)	XPF-ERCC1 and XPG	EXO1 exonuclease
Main polymerase	Pol β (short-patch); pol δ/ε (long-patch)	Pol δ / pol ε	Pol δ
Signature defect	MUTYH-associated polyposis; mtDNA decay	Xeroderma pigmentosum	Lynch syndrome (HNPCC)